M. Hulihan

发表

alpha-Synuclein locus triplication causes Parkinson's disease.

A. Singleton, R. Nussbaum, M. Farrer, 2003, Science.

α-Synuclein Locus Triplication Causes Parkinson's Disease

Janel O. Johnson, A. Singleton, R. Nussbaum, 2003, Science.

Characterization of DCTN1 genetic variability in neurodegeneration

D W Dickson, A. Destée, M. Farrer, 2009, Neurology.

Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

Thomas Meitinger, Bertram Müller-Myhsok, Saskia Biskup, 2004, Neuron.

Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Aldo Quattrone, Nobutaka Hattori, Mariza de Andrade, 2006, JAMA.

α-synuclein locus duplication as a cause of familial Parkinson's disease

Philippe Amouyel, Luc Defebvre, L. Defebvre, 2004, The Lancet.

Uric Acid as a Potential Cue to Screen for Iron Overload

M. Hulihan, A. Mainous, E. Matheson, 2011, The Journal of the American Board of Family Medicine.

COVID-19 and Sickle Cell Disease–Related Deaths Reported in the United States

M. Hulihan, L. Schieve, W. Hooper, 2022, Public health reports.

Iron overload: what is the role of public health?

M. Hulihan, S. Grosse, Althea M. Grant, 2011, American journal of preventive medicine.

Transferrin Saturation and Hospital Length of Stay and Mortality in Medicare Beneficiaries

M. Hulihan, A. Mainous, V. Diaz, 2013, Journal of the American Geriatrics Society.

Calcium channel blocker use and serum ferritin in adults with hypertension

M. Hulihan, V. Diaz, E. Weinberg, 2012, BioMetals.

Lack of mutations in DJ‐1 in a cohort of Taiwanese ethnic Chinese with early‐onset parkinsonism

P. Lockhart, M. Farrer, J. Kachergus, 2004, Movement disorders : official journal of the Movement Disorder Society.

Genetic variation of Omi/HtrA2 and Parkinson's disease.

M. Farrer, M. Hulihan, M. Barcikowska, 2008, Parkinsonism & related disorders.

Collaborative Analysis of (cid:1) -Synuclein Gene Promoter Variability and Parkinson Disease

J. Ioannidis, M. Farrer, M. Hulihan, 2006 .

CE: Understanding the Complications of Sickle Cell Disease.

M. Hulihan, P. Tanabe, Regena Spratling, 2019, The American journal of nursing.

CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell Disease

M. Hulihan, Phoebe G. Thorpe, K. Smith-Whitley, 2017, MMWR. Morbidity and mortality weekly report.

A National Survey of Hemochromatosis Patients

M. Hulihan, A. Mainous, C. J. Everett, 2012, The Journal of the American Board of Family Medicine.

A National Measurement Framework to Assess and Improve Sickle Cell Care in 4 US Regions

Elissa Z. Faro, M. Hulihan, A. King, 2020, Public health reports.

Parkin-proven disease

M. Farrer, M. Hulihan, S. Lincoln, 2003, Neurology.

Lrrk2 R1441 substitution and progressive supranuclear palsy

M. Farrer, M. Hulihan, S. Lincoln, 2006, Neuropathology and applied neurobiology.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

M. Farrer, J. Kachergus, M. Hulihan, 2005, Parkinsonism & related disorders.

LRRK2 R1441G in Spanish patients with Parkinson's disease

M. Farrer, J. Kachergus, M. Hulihan, 2005, Neuroscience Letters.

Pallidonigral TDP-43 pathology in Perry syndrome.

M. Farrer, J. Kachergus, M. Hulihan, 2009, Parkinsonism & related disorders.

Glucosidase-beta variations and Lewy body disorders.

M. Farrer, J. Kachergus, M. Hulihan, 2009, Parkinsonism & related disorders.

Identification of the Human Ubiquitin Specific Protease 31 (USP31) Gene: Structure, Sequence and Expression Analysis

P. Lockhart, M. Farrer, M. Hulihan, 2004, DNA sequence : the journal of DNA sequencing and mapping.

Telomere length and elevated iron: The influence of phenotype and HFE genotype

M. Hulihan, A. Mainous, C. McLaren, 2013, American journal of hematology.

Parkinson's disease in Ireland: Clinical presentation and genetic heterogeneity in patients with parkin mutations

M. Farrer, J. Kachergus, M. Hulihan, 2004, Movement disorders : official journal of the Movement Disorder Society.

Emergency department utilization by Californians with sickle cell disease, 2005–2014

M. Hulihan, E. Vichinsky, T. Coates, 2017, Pediatric blood & cancer.

Longitudinal data collection for sickle cell disease in California : history, goals and challenges

M. Hulihan, Susan T. Paulukonis, Susan Paulukonis, 2015 .

alpha-Synuclein promoter confers susceptibility to Parkinson's disease.

M. Farrer, M. Hulihan, S. Lincoln, 2004, Annals of neurology.

The accuracy of hospital ICD-9-CM codes for determining Sickle Cell Disease genotype

M. Hulihan, P. Lane, Susan T. Paulukonis, 2017, Journal of rare diseases research & treatment.

The impact of chelation therapy on survival in transfusional iron overload: a meta‐analysis of myelodysplastic syndrome

M. Hulihan, A. Mainous, T. Coates, 2014, British journal of haematology.

Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project

M. Hulihan, T. Coates, S. Majumdar, 2021, British journal of haematology.

Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications

Matthew J. Farrer, Dennis W. Dickson, Zbigniew K. Wszolek, 2004 .

Surveillance for Sickle Cell Disease — Sickle Cell Data Collection Program, Two States, 2004–2018

M. Hulihan, L. Schieve, Karon Abe, 2022, Morbidity and mortality weekly report. Surveillance summaries.

Public health surveillance of nonmalignant blood disorders.

M. Hulihan, V. Byams, Meredith A Oakley, 2014, American journal of preventive medicine.

Genomic investigation of α‐synuclein multiplication and parkinsonism

M. Farrer, J. Kachergus, M. Hulihan, 2008, Annals of neurology.

Attitudes toward Management of Sickle Cell Disease and Its Complications: A National Survey of Academic Family Physicians

Navkiran K. Shokar, M. Hulihan, A. Mainous, 2015, Anemia.

Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity

M. Hulihan, S. Oyeku, S. Grosse, 2012, Genetics in Medicine.

Providers’ Perspectives on Treating Patients With Thalassemia

M. Hulihan, L. Feuchtbaum, Taylor J Radke, 2019, Journal of pediatric hematology/oncology.

Linkage disequilibrium and association of MAPT H1 in Parkinson disease.

M. Farrer, M. Hulihan, S. Lincoln, 2004, American journal of human genetics.

Genotype–phenotype correlates in Taiwanese patients with early‐onset recessive parkinsonism

P. Lockhart, M. Farrer, M. Hulihan, 2009, Movement disorders : official journal of the Movement Disorder Society.

Genomewide association, Parkinson disease, and PARK10.

M. Farrer, M. Hulihan, S. Lincoln, 2006, American journal of human genetics.

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

Philippe Amouyel, Luc Defebvre, L. Defebvre, 2004, Lancet.

PINK1 mutations and parkinsonism

P. Matthews, M. Farrer, J. Kachergus, 2008, Neurology.

Incidence of Sickle Cell Trait — United States, 2010

M. Hulihan, Althea M. Grant, Jelili A Ojodu, 2014, MMWR. Morbidity and mortality weekly report.

Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

Timothy Lynch, Jan Aasly, Demetrius M Maraganore, 2005, American journal of human genetics.

Lrrk2 pathogenic substitutions in Parkinson's disease

M. Farrer, J. Kachergus, M. Hulihan, 2005, Neurogenetics.

Analysis of-Synuclein Gene Promoter Variability and Parkinson Disease

J. Ioannidis, M. Farrer, M. Hulihan, 2006 .

DCTN1 mutations in Perry syndrome

M. Farrer, J. Kachergus, M. Hulihan, 2009, Nature Genetics.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Michael K. Hutchinson, P. Lockhart, A. Destée, 2011, American journal of human genetics.

LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study

P. Matthews, M. Farrer, J. Kachergus, 2008, The Lancet Neurology.

Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.

M. Farrer, M. Hulihan, R. Wu, 2007, Parkinsonism & related disorders.

Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease

M. Farrer, J. Kachergus, M. Hulihan, 2007, Neurogenetics.

Clinical features of LRRK2‐associated Parkinson's disease in central Norway

Mathias Toft, M. Farrer, J. Kachergus, 2005, Annals of neurology.

The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Bertram Müller-Myhsok, Manu Sharma, Thomas Gasser, 2004, American journal of human genetics.

α‐Synuclein promoter confers susceptibility to Parkinson's disease

M. Farrer, M. Hulihan, S. Lincoln, 2004 .

Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication

M. Farrer, J. Kachergus, M. Hulihan, 2007, Neurology.

Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism

H. Berendse, M. Farrer, J. Kachergus, 2005, Journal of Neural Transmission.

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008

M. Hulihan, J. Eckman, Althea M. Grant, 2016, Public health reports.

Newborn Screening Practices and Alpha-Thalassemia Detection — United States, 2016

M. Hulihan, M. del Pilar Aguinaga, K. Hassell, 2020, MMWR. Morbidity and mortality weekly report.

State-based surveillance for selected hemoglobinopathies

M. Hulihan, R. Kirby, M. Creary, 2014, Genetics in Medicine.

Public health implications of sickle cell trait: a report of the CDC meeting.

M. Hulihan, H. Atrash, M. Creary, 2011, American journal of preventive medicine.

Newborn Screening Practices for Beta-Thalassemia in the United States

M. Hulihan, Careema Yusuf, Jelili A Ojodu, 2021, International journal of neonatal screening.

Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

M. Farrer, J. Kachergus, M. Hulihan, 2004, Annals of neurology.

DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function

P. Lockhart, M. Farrer, J. Kachergus, 2004, Journal of Medical Genetics.

Fine-mapping and candidate gene investigation within the PARK10 locus

M. Farrer, J. Kachergus, M. Hulihan, 2009, European Journal of Human Genetics.

LRRK2 mutations in Parkinson disease

M. Farrer, J. Kachergus, M. Hulihan, 2005, Neurology.

Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population

M. Farrer, J. Kachergus, M. Hulihan, 2008, Acta neurologica Scandinavica.

Multiplication of the α-synuclein gene is not a common disease mechanism in Lewy body disease

P. Lockhart, M. Farrer, J. Kachergus, 2007, Journal of Molecular Neuroscience.

α-Synuclein missense and multiplication mutations in autosomal dominant Parkinson’s disease

M. Farrer, J. Kachergus, M. Hulihan, 2004, Neuroscience Letters.

ATP13A2 variability in Parkinson disease

M. Farrer, M. Hulihan, S. Lincoln, 2009, Human mutation.

Parkin mutations and early-onset parkinsonism in a Taiwanese cohort.

M. Farrer, M. Hulihan, S. Lincoln, 2005, Archives of neurology.

Rett Syndrome : An Overlooked Diagnosis in Women with Stereotypic Hand Movements , Psychomotor Retardation , Parkinsonism , and Dystonia ?

M. Farrer, J. Kachergus, M. Hulihan, 2007 .

The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia

Sheree L. Boulet, M. Hulihan, S. Boulet, 2013, Genetics in Medicine.

Lrrk2 mutations in South America: A study of Chilean Parkinson's disease

M. Farrer, J. Kachergus, M. Hulihan, 2007, Neuroscience Letters.

Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease

M. Farrer, J. Kachergus, M. Hulihan, 2007, Movement disorders : official journal of the Movement Disorder Society.

Effectiveness of Clinical Decision Support Based Intervention in the Improvement of Care for Adult Sickle Cell Disease Patients in Primary Care

M. Hulihan, A. Mainous, T. Coates, 2018, The Journal of the American Board of Family Medicine.

Elevated transferrin saturation, health-related quality of life and telomere length

M. Hulihan, A. Mainous, C. McLaren, 2013, BioMetals.

Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel

M. Farrer, M. Hulihan, R. Djaldetti, 2008, Journal of Neural Transmission.

Case Ascertainment of Sickle Cell Disease Using Surveillance or Single Administrative Database Case Definitions.

M. Hulihan, Shondelle M. Wilson-Frederick, Susan T. Paulukonis, 2023, Public health reports.

Calcium channel blocker use and serum ferritin in adults with hypertension

M. Hulihan, V. Diaz, E. Weinberg, 2012, BioMetals.

Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease.

M. Farrer, J. Kachergus, M. Hulihan, 2004, Neuroscience letters.

IRon overload screeNing tool (IRON): Development of a tool to guide screening in primary care

M. Hulihan, A. Mainous, C. McLaren, 2011, American journal of hematology.

Iron overload: what is the role of public health?

M. Hulihan, S. Grosse, Althea M. Grant, 2011, American journal of preventive medicine.

Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease.

P. Lockhart, M. Farrer, J. Kachergus, 2004, Journal of molecular neuroscience : MN.

Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population

M. Farrer, J. Kachergus, M. Hulihan, 2008, Acta Neurologica Scandinavica.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Michael K. Hutchinson, P. Lockhart, A. Destée, 2011, American journal of human genetics.

Telomere length and elevated iron: The influence of phenotype and HFE genotype

M. Hulihan, A. Mainous, C. McLaren, 2013, American journal of hematology.

Transferrin Saturation and Hospital Length of Stay and Mortality in Medicare Beneficiaries

M. Hulihan, A. Mainous, V. Diaz, 2013, Journal of the American Geriatrics Society.

Elevated transferrin saturation, health-related quality of life and telomere length

M. Hulihan, A. Mainous, Althea M. Grant, 2013, BioMetals.

Characterization of DCTN1 genetic variability in neurodegeneration

A. Destée, M. Farrer, J. Kachergus, 2009, Neurology.

Incidence of Sickle Cell Trait — United States, 2010

M. Hulihan, Althea M. Grant, Shammara N. Pope, 2014, MMWR. Morbidity and mortality weekly report.

Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents — Selected U.S. States, 2019

M. Hulihan, L. Schieve, W. Hooper, 2022, MMWR. Morbidity and mortality weekly report.